{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T14:21:31Z","timestamp":1788790891983,"version":"build-2803163510"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T00:00:00Z","timestamp":1635811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T00:00:00Z","timestamp":1635811200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Mazandran university of medical sciences, Sari, Iran52","award":["9152"],"award-info":[{"award-number":["9152"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The Sputnik V is a COVID- 19 vaccine developed by the Gamalia institute of epidemiology and microbiology and released on August 11, 2020. We provided independent evidence on side effects and immunogenicity following the administration of the Sputnik V COVID-19 in Iran. In this observational study, the healthcare workers who were vaccinated with the Sputnik V COVID-19 vaccine within February and April 2021 were evaluated. Among a total of 13,435 vaccinated healthcare workers, we received 3236 self-declaration reports of Sputnik V associated adverse events with the mean age 39.32\u2009\u00b1\u200910.19\u00a0years old which 38.8% were men and 61.2% were women. Totally 68.8% of females versus 66.2% of males reported side effects after receiving the first dose and 31.2% of females versus 33.8% of males reported side effects after the second dose of vaccine. The most common side effect was a pain in the injection site (56.9%), fatigue (50.9%), body pain (43.9%), headache (35.7%), fever (32.9%), joint pain (30.3%), chilling (29.8%) and drowsiness (20.3%). Side effects of the vaccine were significantly more frequent in females and younger individuals. Among a total of 238 participants, more than 90% after the first and second dose of vaccine had a detectable level of SARS-CoV-2 RBD antibody and SARS-CoV-2 neutralizing antibody. Although the overall rate of adverse effects was higher than the interim results from randomized controlled trials, our findings support the manufacturer\u2019s reports about the high humoral immunogenicity of vaccine against COVID-19.<\/jats:p>","DOI":"10.1038\/s41598-021-00963-7","type":"journal-article","created":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T11:03:37Z","timestamp":1635851017000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Side effects and Immunogenicity following administration of the Sputnik V COVID-19 vaccine in health care workers in Iran"],"prefix":"10.1038","volume":"11","author":[{"given":"Farhang","family":"Babamahmoodi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majid","family":"Saeedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Alizadeh-Navaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akbar","family":"Hedayatizadeh-Omran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Abbas","family":"Mousavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gasem","family":"Ovaise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirafkan","family":"Kordi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Akbari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazaher","family":"Azordeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Ahangarkani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Alikhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,2]]},"reference":[{"key":"963_CR1","unstructured":"WHO Coronavirus Disease (COVID-19) Dashboard. In: World Health Organization; 2021. https:\/\/covid19.who.int. Accessed 20 Sept 2021."},{"key":"963_CR2","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1080\/21645515.2016.1238535","volume":"13","author":"IV Dolzhikova","year":"2017","unstructured":"Dolzhikova, I. V. et al. Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I\/II trial in healthy adults in Russia. Hum. Vaccin. Immunother. 13, 613\u2013620. https:\/\/doi.org\/10.1080\/21645515.2016.1238535 (2017).","journal-title":"Hum. Vaccin. Immunother."},{"key":"963_CR3","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/s0140-6736(21)00234-8","volume":"397","author":"DY Logunov","year":"2021","unstructured":"Logunov, D. Y. et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: An interim analysis of a randomised controlled phase 3 trial in Russia. Lancet (London, England) 397, 671\u2013681. https:\/\/doi.org\/10.1016\/s0140-6736(21)00234-8 (2021).","journal-title":"Lancet (London, England)"},{"key":"963_CR4","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ymthe.2004.07.013","volume":"10","author":"N Tatsis","year":"2004","unstructured":"Tatsis, N. & Ertl, H. C. Adenoviruses as vaccine vectors. Mol. Ther. J. Am. Soc. Gene Ther. 10, 616\u2013629. https:\/\/doi.org\/10.1016\/j.ymthe.2004.07.013 (2004).","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"963_CR5","doi-asserted-by":"publisher","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","volume":"147","author":"E von Elm","year":"2007","unstructured":"von Elm, E. et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. Ann. Intern. Med. 147, 573\u2013577. https:\/\/doi.org\/10.7326\/0003-4819-147-8-200710160-00010 (2007).","journal-title":"Ann. Intern. Med."},{"key":"963_CR6","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/s41587-020-0631-z","volume":"38","author":"CW Tan","year":"2020","unstructured":"Tan, C. W. et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. Nat. Biotechnol. 38, 1073\u20131078. https:\/\/doi.org\/10.1038\/s41587-020-0631-z (2020).","journal-title":"Nat. Biotechnol."},{"key":"963_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10071428","author":"A Riad","year":"2021","unstructured":"Riad, A. et al. Prevalence of COVID-19 vaccine side effects among healthcare workers in the Czech Republic. J. Clin. Med. https:\/\/doi.org\/10.3390\/jcm10071428 (2021).","journal-title":"J. Clin. Med."},{"key":"963_CR8","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/s1473-3099(21)00224-3","volume":"21","author":"C Menni","year":"2021","unstructured":"Menni, C. et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: A prospective observational study. Lancet. Infect. Dis 21, 939\u2013949. https:\/\/doi.org\/10.1016\/s1473-3099(21)00224-3 (2021).","journal-title":"Lancet. Infect. Dis"},{"key":"963_CR9","first-page":"408","volume":"81","author":"V Pagotto","year":"2021","unstructured":"Pagotto, V. et al. Active monitoring of early safety of Sputnik V vaccine in Buenos Aires, Argentina. Medicina 81, 408\u2013414 (2021).","journal-title":"Medicina"},{"key":"963_CR10","first-page":"20","volume":"20","author":"M Montalti","year":"2021","unstructured":"Montalti, M. et al. ROCCA study protocol and interim analysis on safety of Sputnik V vaccine (Gam-COVID-Vac) in the Republic of San Marino: An observational study using active surveillance. medRxiv 20, 20 (2021).","journal-title":"medRxiv"},{"key":"963_CR11","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1056\/NEJMc2101667","volume":"384","author":"F Krammer","year":"2021","unstructured":"Krammer, F. et al. Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine. N. Engl. J. Med. 384, 1372\u20131374. https:\/\/doi.org\/10.1056\/NEJMc2101667 (2021).","journal-title":"N. Engl. J. Med."},{"key":"963_CR12","doi-asserted-by":"publisher","first-page":"n308","DOI":"10.1136\/bmj.n308","volume":"372","author":"J Wise","year":"2021","unstructured":"Wise, J. Covid-19: People who have had infection might only need one dose of mRNA vaccine. BMJ (Clin. Res. Ed.) 372, n308. https:\/\/doi.org\/10.1136\/bmj.n308 (2021).","journal-title":"BMJ (Clin. Res. Ed.)"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-00963-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-00963-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-00963-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T16:59:55Z","timestamp":1670086795000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-00963-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,2]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["963"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-00963-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,2]]},"assertion":[{"value":"12 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21464"}}